-
Optimal systemic therapy in men with low-volume prostate cancer. Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-03-06 Akshat Saxena, Jack Andrews, Alan Haruo Bryce, Irbaz Bin Riaz
Low-volume prostate cancer is an established prognostic category of metastatic hormone-sensitive prostate cancer. However, the term is often loosely used to reflect the low burden of disease across different prostate cancer states. This review explores the definitions of low-volume prostate cancer, biology, and current evidence for treatment. We also explore future directions, including the impact
-
Prevention, diagnosis, and treatment of urolithiasis in geriatric patients - differences, similarities and caveats in comparison to the general population. Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-03-06 Tarek A Schrag, Danielle Diarra, Julian Veser
Purpose of the review is to address management and prevention of urolithiasis in elderly patients examining the dynamic interplay between general measures, dietary adjustments, lifestyle modifications, and targeted pharmacological and/ or surgical interventions. The goal is to provide understanding of the evolving strategies required for effective urolithiasis prevention in the geriatric population
-
Preoperative geriatric assessment of urological patients: a narrative review. Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-03-05 Marcus Köller
The proportion of older people is increasing disproportionately. The age between 60 and 65 years is seen as the transition to 'old age'. Frailty is a risk factor for morbidity, mortality, and complications in the context of medical interventions or adverse effects of drug therapies. One of the core components of frailty, the age-related loss of muscle mass, is sarcopenia. Is there an influence of frailty
-
Metastasis-directed therapy in oligometastatic prostate cancer. Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-03-01 Marcin Miszczyk, Timo Soeterik, Giancarlo Marra, Akihiro Matsukawa, Shahrokh F Shariat
To summarize the recent findings on the subject of metastasis-directed therapy (MDT) in the treatment of oligometastatic prostate cancer (omPCa).
-
Effect of increasing age and ureteral stent implantation on urinary tract infections after kidney transplantation - update of recent literature. Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-03-01 Haris Omic, Michael Eder
This review aims to present the recent literature regarding effects of aging and ureteral stent implantation (UrS) on the risk of urinary tract infections (UTIs) in kidney transplant (KTX) recipients.
-
Definitions, outcomes and perspectives for oligometastatic bladder cancer: towards a standardized terminology. Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-03-01 Giorgio Calleris, Markus von Deimling, Claudia Kesch, Francesco Soria, Paolo Gontero, Guillaume Ploussard, Ekaterina Laukhtina, Benjamin Pradère
Oligometastatic (om) cancer is considered as a transitional state in between locally confined disease and widespread metastases, accessible to a multimodal treatment, combining systemic and local therapy. In urothelial bladder cancer (BCa), the definitions and the approaches to this condition are poorly standardised and mainly based on retrospective data. We aim to portray the framework for uro-oncologic
-
The histomorphology of the senescent kidney - the clinical relevance of specimen and biopsy findings in the elderly native kidneys. Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-02-27 Nicolas Kozakowski
Renal pathology is crucial in diagnosing the ageing kidney. Recent technological advances enabled high-resolution molecular investigations into the complex mechanisms of ageing and senescence.
-
Testicular cancer with small metastatic burden: optimal approach in 2024. Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-02-03 Kit L Yuen, Kshitij Pandit, Dhruv Puri, Nuphat Yodkhunnatham, Aditya Bagrodia
Recent advancements in the management of clinical stage II (CS II) testicular cancer have transformed it into a predominantly curable condition. This success in treatment advancements has markedly extended patient survival. However, these treatments carry risks and morbidities, which is important to consider given the disease's impact on young men and the emerging understanding of long-term treatment
-
Current evidence on local therapy in oligometastatic prostate cancer. Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-02-02 Spyridon P Basourakos, Grant Henning, R Jeffrey Karnes
Metastatic prostate cancer (PCa) continues to be an invariably fatal condition. While historically, de-novo metastatic PCa was primarily treated with androgen deprivation therapy (ADT) and systemic therapy, there is a growing trend toward incorporating local treatments in the early management of the disease. This is particularly applicable to men with oligometastatic PCa (OMPC), which represents an
-
Beyond the knife: strategic patient selection for cytoreductive nephrectomy. Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-01-19 Stephan Brönimann, Yasser Ged, Nirmish Singla
To evaluate the current role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) within the context of evolving treatment paradigms, focusing on implications for patient selection.
-
What is in the pipeline for new treatments for bladder pain syndrome/ interstitial cystitis? Curr. Opin. Urol. (IF 2.5) Pub Date : 2024-01-04 Diogo Dias, Pedro Abreu Mendes, Paulo Dinis Oliveira, Rui Almeida Pinto
Despite available treatments, many bladder pain syndrome/interstitial cystitis (BPS/IC) patients continue to have poor quality of life. Thus, there is an urge for new therapies. Our manuscript aims to review papers about BPS/IC treatments published in the last 2 years.
-
Latest insights into the pathophysiology of bladder pain syndrome/interstitial cystitis. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-12-21 Jure Tornic, Daniel Engeler
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a common medical problem in both sexes affecting people of all ages. Patients might report overactive bladder symptoms with additional bladder pain at maximum bladder filling, during and after micturition. This review aims to highlight pathophysiological mechanisms associated with this disease.
-
Digital health innovations in urology: telemedicine, wearables, and mobile applications - a systematic review of literature. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-12-04 Nithesh Naik, Ali Talyshinskii, Jens Rassweiler, B M Zeeshan Hameed, Bhaskar K Somani
There are enough publications on the use of telemedicine, wearable devices, and mobile applications in urology; however, their collective impact on urological care has not been adequately studied. This review seeks to address this deficiency by providing a descriptive analysis of the recent use of telemedicine, wearable technology, and mobile applications in urology as well as elucidating their associated
-
The urothelial barrier in interstitial cystitis/bladder pain syndrome: its form and function, an overview of preclinical models. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-11-21 Charlotte van Ginkel,Robert E Hurst,Dick Janssen
PURPOSE OF REVIEW Investigating bladder pain syndrome/interstitial cystitis (IC/BPS) preclinically is challenging. Various research models have been used to mimic the urothelial barrier closely and replicate the disease. The aim of this review is to discuss preclinical research related to the urothelial barrier in context of IC/BPS. RECENT FINDINGS In vivo models mimic IC/BPS mainly with toxic substances
-
Bladder pain syndrome AKA interstitial cystitis - a condition with severe unmet medical need: an exploration of brimapitide as a potential treatment opportunity. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-11-20 Erich Taubert, Frank van de Aa, John Heesakkers
The purpose of this article is to present recent findings of KU002 (brimapitide) as a novel treatment option for interstitial cystitis/bladder pain syndrome (IC/BPS).
-
Single use flexible ureteroscopes: a review of current technologies and cost effectiveness analysis. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-11-15 Ali Talyshinskii, Vineet Gauhar, Daniele Castellani, Thomas Knoll, Kaushikkumar Shah, Shaw P Wan, Bhaskar K Somani
Flexible ureteroscopy (fURS) has evolved into both diagnostic and therapeutic modalities. Our review discusses the cost-effectiveness of single use flexible ureteroscopes (su-fURS) and the use of these instruments in routine urological practice.
-
Leveraging behavioral modification technology for the prevention of kidney stones. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-11-14 Leonid I Aksenov, Necole M Streeper, Charles D Scales
The purpose of this review is to examine the use of technology to help promote and maintain behaviors that decrease stone recurrence.
-
ChatGPT in urology practice: revolutionizing efficiency and patient care with generative artificial intelligence. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-11-14 Carlotta Nedbal, Nitesh Naik, Daniele Castellani, Vineet Gahuar, Robert Geraghty, Bhaskar Kumar Somani
ChatGPT has emerged as a potentially useful tool for healthcare. Its role in urology is in its infancy and has much potential for research, clinical practice and for patient assistance. With this narrative review, we want to draw a picture of what is known about ChatGPT's integration in urology, alongside future promises and challenges.
-
Restoring the barrier of chronically damaged urothelium using chondroitin sulfate glycosaminoglycan-replenishment therapy: a preclinical study using a chronic experimental model for bladder pain syndrome/interstitial cystitis and reflections on lately published similar models. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-11-14 Boy B Rozenberg, Charlotte J van Ginkel, Dick A W Janssen
This study aims to further understand the physiological mechanism of chondroitin sulfate treatment on the urinary bladder in cases of inflammation, by investigating the effect of chondroitin sulfate therapy on recovery of urothelial barrier in an in-vitro chronic injury model.
-
Should endoscopic laser excision be offered as the first-line management for patients with eroded mesh? Outcomes of a systematic review of literature. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-11-07 Francesco Ripa,Dmitry Enikeev,Ali Talyshinskii,Patrick Juliebø-Jones,Lazaros Tzelves,Panagiotis Kallidonis,Bhaskar Somani
PURPOSE OF REVIEW Mesh erosions following previous synthetic sling/mesh surgery for stress urinary incontinence (SUI) have become increasingly common. This systematic review provides evidence for the role of laser excision as a first-line management in patients with eroded mesh. RECENT FINDINGS Fourteen articles (173 patients) were included for the final review. Among these, 138 patients (79.8%) were
-
Current position of neuromodulation for bladder pain syndrome/interstitial cystitis. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-11-07 Harry J Kendall,Julia Schrijvers,John P F A Heesakkers
PURPOSE OF REVIEW Despite established effectiveness in overactive bladder and nonobstructive retention, neuromodulation's application in interstitial cystitis/bladder pain syndrome (IC/BPS) remains a topic of ongoing research. The purpose of this article is to review recent developments in neuromodulation as treatment of IC/BPS offering guidance for healthcare practitioners dealing with IC/BPS cases
-
AI-powered radiomics: revolutionizing detection of urologic malignancies. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-11-02 David G Gelikman,Soroush Rais-Bahrami,Peter A Pinto,Baris Turkbey
PURPOSE OF REVIEW This review aims to highlight the integration of artificial intelligence-powered radiomics in urologic oncology, focusing on the diagnostic and prognostic advancements in the realm of managing prostate, kidney, and bladder cancers. RECENT FINDINGS As artificial intelligence continues to shape the medical imaging landscape, its integration into the field of urologic oncology has led
-
Virtual reality vs. physical models in surgical skills training. An update of the evidence. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-11-02 Baldev Chahal, Abdullatif Aydin, Kamran Ahmed
Simulation is a key component of surgical training, enabling trainees to develop their skills in a safe environment. With simulators broadly grouped into physical models and virtual-reality (VR) simulators, it is important to evaluate the comparative effectiveness of the simulator types in terms of validity as well as cost. The review aims to compare the benefits and drawbacks of novel VR and physical
-
Overview of current applications and trends in artificial intelligence for cystoscopy and transurethral resection of bladder tumours. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-10-31 Atsushi Ikeda,Hirokazu Nosato
PURPOSE OF REVIEW Accurate preoperative and intraoperative identification and complete resection of bladder cancer is essential. Adequate postoperative follow-up and observation are important to identify early intravesical recurrence or progression. However, the accuracy of diagnosis and treatment is dependent on the knowledge and experience of the physicians. Artificial intelligence (AI) can be an
-
Measuring quality of life in patients with kidney stone disease: is it the future in endourology? Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-10-30 Anh Khoi Vo, Bhaskar K Somani, Øyvind Ulvik, Christian Beisland, Christian Seitz, Patrick Juliebø-Jones
Kidney stone disease is recognized to negatively impact quality of life. This pertains to acute episodes, surgical interventions and even during asymptomatic periods. Over time there has been increased attention towards assessing this subjective parameter, including as a determinant of treatment success. Our aim was to evaluate the current status and emerging trends in this field.
-
Navigation systems and 3D imaging in percutaneous nephrolithotripsy: improving outcomes and safety. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-10-30 Athanasios Bouchalakis, Bhaskar Kumar Somani, Estevao Lima, Marie-Claire Rassweiler-Seyfried, Charalampos Mamoulakis, Theodoros Tokas
Percutaneous nephrolithotripsy (PCNL) is the first-line management option for large kidney stones (>2 cm). It remains, however, a demanding procedure with considerable morbidity. The present narrative review summarizes recent knowledge from original research studies investigating navigation systems/three-dimensional (3D) imaging in PCNL, particularly on publications during the past 12-18 months.
-
Chronic pelvic pain; more than just the bladder. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-10-13 Bert Messelink, Ida Flink, Ana Dos Santos, Corine Adamse
Chronic pelvic pain is much of a burden to those who suffer from it. Additionally, in many patients medical doctors, such as urologists are unable to identify a cause or clear pathology that can explain the pain. Still numerous patients and doctors keep on searching for a cause, focussing particularly on the pelvic organs. Lots of diagnostics and treatment methods are used but often without success
-
Prognostic impact of serum testosterone in metastatic hormone-naive prostate cancer: a systematic review and meta-analysis. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-09-26 Ignacio Puche-Sanz, Peter Chiu, Ana C Morillo, Enrique Gomez-Gomez
In daily practice, there is an unmet medical need for biomarkers that facilitate therapeutic decision-making in the metastatic hormone sensitive prostate cancer (mHSPC) scenario. Although recent studies have highlighted the potential of testosterone as a prognostic and predictive marker in prostate cancer, the evidence is controversial. The objective of this review was to summarize and analyze the
-
Ureterorenoscopy for stone disease in pregnancy: a literature review and update. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-09-20 Sebastian Graf, Bhaskar K Somani
Management of stone disease in pregnancy poses a challenge for all healthcare professionals involved in their care. During pregnancy, there is an increase in the incidence of urolithiasis. Major technological and procedural advances have been seen in the last decade for endoscopic management of urolithiasis. The purpose of this review is to provide a comprehensive workup of available literature on
-
Research on texture images and radiomics in urology: a review of urological MR imaging applications. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-09-19 Antoine Valeri, Truong An Nguyen
Tumor volume and heterogenicity are associated with diagnosis and prognosis of urological cancers, and assessed by conventional imaging. Quantitative imaging, Radiomics, using advanced mathematical analysis may contain information imperceptible to the human eye, and may identify imaging-based biomarkers, a new field of research for individualized medicine. This review summarizes the recent literature
-
Detection of urological cancers by the signature of organic volatile compounds in urine, from dogs to electronic noses. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-09-06 Oumar Gaye, Cheikh Bintou Fall, Mohamed Jalloh, Babacar Faye, Marc Jobin, Olivier Cussenot
Urine volatile organic compound (VOC) testing for early detection of urological cancers is a minimally invasive and promising method. The objective of this review was to present the results of recently published work on this subject.
-
Triple therapy in metastatic hormone-sensitive prostate cancer. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-09-04 Igor Tsaur, Cristian Mirvald, Cristian Surcel
Over the last years, there have been striking changes in the management of metastatic hormone-sensitive prostate cancer (mHSPC) based on survival advantage of combining either a new hormonal agent (NHA) or docetaxel (D) with androgen deprivation therapy (ADT). Some of these studies primarily assessing doublet treatment included men who underwent concomitant or sequential treatment with D. Most recently
-
The quality of life value in uro-oncological patients. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-09-01 Marcello Della Corte,Francesco Porpiglia,Enrico Checcucci
-
Urinary continence in high-risk prostate cancer after robot-assisted radical prostatectomy. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-08-31 Xiaobo Wu, Chris Ho-Ming Wong, Giorgio Gandaglia, Peter Ka-Fung Chiu
Urinary incontinence is common postoperative complication following robot-assisted radical prostatectomy (RARP) in patients with prostate cancer (PCa). Despite the increasing adoption of RARP in the treatment of high-risk PCa (HRPC), concerns persist regarding the adequacy of reported continence outcomes in this subgroup. This review aims to illuminate the state of continence recovery in HRPC patients
-
Use of genomic markers to improve epidemiologic and clinical research in urology. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-08-30 Géraldine Cancel-Tassin, Stella Koutros
Urologic cancers result from the appearance of genomic alterations in the target organ due to the combination of genetic and environmental factors. Knowledge of the genomic markers involved in their etiology and mechanisms for their development continue to progress. This reviewed provides an update on recent genomic studies that have informed epidemiologic and clinical research in urology.
-
Urinary outcomes of new ultra-minimally invasive treatments for prostate cancers. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-08-23 Sabrina De Cillis, Nadir Osman, Cyrille Guillot-Tantay, Francois Hervé, Mikolaj Przydacz, Manuela Tutolo, Gokhan Culha, Paolo Geretto, Fabiana Cancrini, Enrico Checcucci, Veronique Phé
The aim of this narrative review is to evaluate the current available literature on urinary outcomes following cryotherapy and high-intensity focused ultrasound (HIFU) for localized prostate cancer (PCa).
-
Optimal combination therapy for metastatic hormone-sensitive prostate cancer: new evidence, challenges and unanswered questions. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-08-22 Fabio Zattoni, Pawel Rajwa, Giorgio Gandaglia
To evaluate the evidence supporting treatment intensification in mHSPC, with a focus on possible indications for treatment in each clinical setting.
-
Pembrolizumab in mCRPC - Combination therapies as breakthrough to success? Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-08-22 Stefan Plas, Andreas Pircher, Isabel Heidegger
Immune checkpoint inhibitors (ICIs) have shown promising antitumor activity in various malignant diseases. This narrative review provides an update on ongoing clinical studies investigating the only FDA-approved ICI programmed death receptor 1 (PD-1) inhibitor pembrolizumab in mono- and combination therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).
-
New technologies for nephron-sparing surgery in upper urinary tract cancers. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-08-21 Andrea Gallioli, Giuseppe Basile, Angelo Territo, Alberto Breda
Nephron-sparing surgery (NSS) is the preferred treatment in patients with low-risk upper tract urothelial carcinoma (UTUC). Improving both instruments and topical chemotherapy regimens efficacy is crucial to achieve better outcomes. The purpose of this review is to summarize the most recent evidence on technological advances for the conservative management of UTUC with implications on diagnosis and
-
Endemic statistical paradoxes in epidemiologic studies distort knowledge on prostate cancer: mitigation and caution of fallacies in prostate cancer causal epidemiological studies. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-08-13 Olivier Cussenot,Gaelle Fromont,Géraldine Cancel-Tassin,Freddie C Hamdy,Richard M Martin
PURPOSE OF REVIEW Many studies on epidemiology of prostate cancer (PCa) are based on a diagnosis of PCa using PSA (prostate-specific antigen) level. However, biases can distort the interpretation of the results, which in turn limits policy and decision making on public health prevention strategies or clinical guidelines. The main confusion is to interpret the posterior probability of the outcome following
-
The role of nuclear medicine tracers for prostate cancer surgery: from preoperative to intraoperative setting. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-08-03 Francesco Barletta, Francesco Ceci, Roderick C N van den Bergh, Pawel Rajwa, Francesco Montorsi, Alberto Briganti, Giorgio Gandaglia
There has been a growing interest in the use of novel molecular imaging modalities for the management of prostate cancer (PCa), spanning from diagnostic to therapeutic settings. The aim of this review is to provide a comprehensive overview of recently published studies investigating the use of novel nuclear medicine tracers across different stages of PCa management.
-
Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out? Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-07-26 Celestia S Higano, Heather H Cheng
The landscape for first-line therapy (1L) of metastatic castration-resistant prostate cancer (mCRPC) is rapidly shifting. In the past 2 years, three phase 3 trials have examined the addition of a poly-ADP ribose polymerase inhibitor (PARPi) to an androgen receptor-signaling inhibitor (ARSI) in 1L. The FDA and the EMA recently considered whether one of these combinations should be approved for "all
-
Metastasis-directed treatment in kidney cancer. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-07-06 Jamaal C Jackson, Antonio Franco, Dian Wang, Riccardo Autorino, Srinivas Vourganti
To provide a critical overview of the latest evidence on the role of metastasis-direct treatment (MDT) in the management of metastatic renal cell carcinoma (mRCC).
-
Techniques and outcomes of percutaneous tumour ablation for small renal masses. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-07-06 Angela Pecoraro, Riccardo Campi, Michele Marchioni
Small renal masses suspected to be malignant have little potential for metastasis and disease-related mortality. Surgery remains the standard care but represents overtreatment in many cases. Percutaneous ablative technique, especially thermal ablation has emerged as a valid alternative.
-
Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancer. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-07-03 Mario de Angelis, Giuseppe Basile, Carlo Maria Scornajenghi, Vincenzo Asero, Francesco Del Giudice, Marco Moschini
Radical cystectomy is the standard of care for patients with localized muscle-invasive bladder cancer (MIBC). In this context, bladder-sparing strategies (BSS) have been investigated as viable alternatives for patients who are unfit for radical cystectomy or aim to preserve their bladder without compromising oncological outcomes. This review aims to provide the most up-to-date evidence on BSSs as an
-
Immunotherapy combinations for metastatic castration-resistant prostate cancer - failed trials and future aspects. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-07-03 Susan F Slovin
Immunotherapy, a treatment modality currently synonymous with immune checkpoint blockade remains a challenge for prostate cancer. Despite multiple phase 3 trials using checkpoint inhibitors in combinatorial approaches, there have been no benefits to date in overall survival or radiographic progression free survival. However, newer strategies prevail that are directed to a variety of unique cell surface
-
Organ-sparing treatment for T1 and T2 penile cancer: an updated literature review. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-06-29 Carlo Maria Scornajenghi, Vincenzo Asero, Eugenio Bologna, Giuseppe Basile, Mario De Angelis, Marco Moschini, Francesco Del Giudice
Penile cancer (PeCa) is an orphan disease due to its rare incidence in high-income countries. Traditional surgical options for clinical T1-2 disease, including partial and total penectomy, can dramatically affect patient's quality of life and mental health status. In selected patients, organ-sparing surgery (OSS) has the potential to remove the primary tumor with comparable oncologic outcomes while
-
The spread of retzius-sparing robotic prostatectomy: an update after 10 years. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-06-21 Antonio Galfano,Silvia Secco,Alberto Olivero,Aldo Massimo Bocciardi,Paolo Dell'Oglio
PURPOSE OF REVIEW Objective of our work is to provide an update of the state of the art concerning Retzius-sparing robot-assisted radical prostatectomy (RS-RARP) and to give a possible vision on the future developments of this new approach. RECENT FINDINGS A nonsystematic literature review has been conducted, finding 27 comparative studies and 24 reviews published up to April 15, 2023. Most of these
-
The resurgence of methenamine hippurate in the prevention of recurrent UTIs in women- a systematic review. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-06-20 Saurabh Kale, Bhaskar K Somani
Recurrent urinary tract infections (rUTIs) in women are prevalent and difficult to manage. The rise of antimicrobial resistance makes it prudent to re-investigate the role of nonantimicrobial agents in the prevention of RUTIs. We wanted to evaluate randomised controlled trials (RCTs) that employed methenamine hippurate as a therapy or prophylactic in adult women with rUTIs.
-
Recent developments in perioperative combination therapy in muscle-invasive bladder cancer. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-06-03 Jan-Jaap J Mellema, Bas W G van Rhijn, Michiel S van der Heijden
A summary of recent literature to provide a comprehensive overview of the current state of systemic perioperative treatment combinations for muscle-invasive bladder cancer (MIBC).
-
Salvage lymphadenectomy after primary therapy with curative intent for prostate cancer. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-05-12 Fahad Quhal, Piotr Bryniarski, Juan Gomez Rivas, Giorgio Gandaglia, Shahrokh F Shariat, Pawel Rajwa
To provide a summary of the current literature on salvage lymph node dissection (sLND) in patients with nodal recurrent prostate cancer (PCa) with focus on imaging, the extent of sLND and oncologic outcomes.
-
Role of inguinal and pelvic lymph node dissection for primary urethral carcinoma: a systematic review Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-05-10 Maxim Kochergin, Omar Fahmy, Anastasios D. Asimakopoulos, Georgios Gakis
Purpose of review Primary urethral carcinoma (PUC) is a rare urologic tumor. There is limited evidence on this entity. This review summarizes the existing evidence on lymph node dissection (LND) in patients with PUC. Recent findings We performed a systematic search of the PubMed, EMBASE, and Web of Science databases to evaluate the impact of inguinal and pelvic LND on the oncological outcomes of
-
Evolution and current applications of endoscopic combined intrarenal surgery: a scoping review from back to the future Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-05-10 Vineet Gauhar, Olivier Traxer, Demetra Fuligni, Carlo Brocca, Andrea Bendetto Galosi, Jeremy Yuen-Chun Teoh, Daniele Castellani
Purpose of review To systematically review the evolution of techniques, technology, clinical utility, limitations and possible future applications of endoscopic combined intrarenal surgery (ECIRS) for ureteral and kidney stones. Recent findings The literature search was performed on 18th January 2023 using PubMed, EMBASE and Scopus. 35 studies were included. Among them, six were reviews. Since its
-
The role of primary retroperitoneal lymph node dissection in the treatment of stage II seminoma Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-05-05 Silvan Sigg, Christian Daniel Fankhauser
Purpose of review Stage II seminoma is responsive to chemo- or radiotherapy with a progression-free survival of 87–95% at 5 years but at the cost of short- and long-term toxicity. After evidence about these long-term morbidities emerged, four surgical cohorts investigating the role of retroperitoneal lymph node dissection (RPLND) as a treatment option for stage II disease were initiated. Recent findings
-
Retrograde intra renal surgery and safety: pressure and temperature. A systematic review Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-05-05 Frédéric Panthier, Felipe Pauchard, Olivier Traxer
Purpose of review Retrograde intra renal surgery (RIRS) with laser lithotripsy represents the gold-standard to treat renal stones up to 20 mm. Controlling intraoperative parameters such as intrarenal pressure (IRP) and temperature (IRT) is mandatory to avoid complications. This article reviews advances in IRP and IRT over the last 2 years. Recent findings We conducted a PubMed/Embase search and reviewed
-
Nerve-sparing technique in RPLND for testicular cancer. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-05-03 Sunny Nalavenkata, Thomas Li, Manish I Patel
The management of testicular cancer has evolved over time with multimodal therapy. Retroperitoneal lymph node dissection (RPLND), which is a complex and potentially morbid treatment option, remains the mainstay in surgical treatment. This article reviews the surgical template, approach and anatomical considerations with regards to nerve spare in RPLND.
-
Role of lymphadenectomy during primary surgery for kidney cancer Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-04-11 Kensuke Bekku, Tatsushi Kawada, Takafumi Yanagisawa, Pierre I. Karakiewicz, Shahrokh F. Shariat
Purpose of review Lymph node dissection (LND) during radical nephrectomy (RN) for renal cell carcinoma (RCC) is not considered as a standard. The emergence of robot-assisted surgery and effective immune checkpoint inhibitors (ICI) in recent years may change this and lymph node (LN) staging has become easier and has a clinical impact. In this review, we aimed to reconsider the role of LND today. Recent
-
Extended pelvic lymph node dissection in muscle invasive bladder cancer Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-04-07 Andrew B. Katims, Bernard H. Bochner
Purpose of review Bilateral pelvic lymph node dissection (PLND) at the time of radical cystectomy (RC) provides important staging information and oncologic benefit in patients with bladder cancer. The optimal extent of the PLND remains controversial. Our aim is to highlight nodal mapping studies and the data that guides optimization of both staging and oncologic outcomes. We then review contemporary
-
Retrograde intrarenal surgery for stones associated with renal anomalies: caliceal diverticulum, horseshoe kidney, medullary sponge kidney, megacalycosis, pelvic kidney, uretero-pelvic junction obstruction. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-04-05 Mariela Corrales, Alba Sierra
Nowadays, due to the increase of imaging diagnosis, we identify easily renal anomalies, and we can choose between a wide range of armamentarium to treat symptomatic stones in those challenging cases. However, there is a lack of evidence and consensus on its use. The aim of this narrative review is to collect all the available data about safety and efficacity of retrograde intrarenal surgery (RIRS)
-
Robotic-assisted retroperitoneal lymph node dissection for testicular cancer. Curr. Opin. Urol. (IF 2.5) Pub Date : 2023-04-05 Sofia Gereta, Michael Hung, Jim C Hu
Robotic-assisted retroperitoneal lymph node dissection (R-RPLND) is an emerging surgical option for testicular cancer with less morbidity than open RPLND. We outline the operative technique used at our center and review contemporary evidence in the advancement of R-RPLND.